磷酸二酯酶5抑制剂在心血管疾病治疗中的应用

被引：4

作者：

黄震华

机构：

[1] 上海交通大学医学院附属第九人民医院心血管病研究室

来源：

中国新药与临床杂志 | 2015年 / 34卷 / 06期

关键词：

磷酸二酯酶抑制剂; 心力衰竭,充血性; 高血压,肺性; 雷诺病;

D O I：

10.14109/j.cnki.xyylc.2015.06.002

中图分类号：

R54 [心脏、血管（循环系）疾病];

学科分类号：

100201 [内科学];

摘要：

磷酸二酯酶5抑制剂通过抑制磷酸二酯酶,延迟环磷酸鸟苷的分解,从而发挥血管平滑肌扩张作用。磷酸二酯酶5抑制剂在心力衰竭、肺动脉高压、高原肺水肿、高原肺动脉高压、高血压、雷诺综合征等的治疗中发挥重要作用。

引用

页码：409 / 412

页数：4

共 11 条

[1]

肺动脉高压的药物治疗 [J].

田丹 ;

周达新 ;

吕迁洲 .

中国新药与临床杂志, 2013, 32 (03) :181-186

[2]

Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension [J].

Oliver, James J. ;

Dear, James W. ;

Webb, David J. .

HYPERTENSION, 2010, 56 (01) :62-67

[3]

Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart [J].

Lu, Zhongbing ;

Xu, Xin ;

Hu, Xinli ;

Lee, Sangjin ;

Traverse, Jay H. ;

Zhu, Guangshuo ;

Fassett, John ;

Tao, Yi ;

Zhang, Ping ;

dos Remedios, Cris ;

Pritzker, Marc ;

Hall, Jennifer L. ;

Garry, Daniel J. ;

Chen, Yingjie .

CIRCULATION, 2010, 121 (13) :1474-U48

[4]

Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure:: A double-blind, placebo-controlled clinical trial [J].

Behling, Alice ;

Rohde, Luis E. ;

Colombo, Fernanda C. ;

Goldraich, Livia A. ;

Stein, Ricardo ;

Clausell, Nadine .

JOURNAL OF CARDIAC FAILURE, 2008, 14 (03) :189-197

[5]

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension [J].

Lewis, Gregory D. ;

Shah, Ravi ;

Shahzad, Khurram ;

Camuso, Janice M. ;

Pappagianopoulos, Paul P. ;

Hung, Judy ;

Tawakol, Ahmed ;

Gerszten, Robert E. ;

Systrom, David M. ;

Bloch, Kenneth D. ;

Semigran, Marc J. .

CIRCULATION, 2007, 116 (14) :1555-1562

[6]

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility [J].

Nagendran, Jayan ;

Archer, Stephen L. ;

Soliman, Daniel ;

Gurtu, Vikram ;

Moudgil, Rohit ;

Haromy, Alois ;

St. Aubin, Chantal ;

Webster, Linda ;

Rebeyka, Ivan M. ;

Ross, David B. ;

Light, Peter E. ;

Dyck, Jason R. B. ;

Michelakis, Evangelos D. .

CIRCULATION, 2007, 116 (03) :238-248

[7]

Long-term use of sildenafil in the therapeutic management of heart failure [J].

Guazzi, Marco ;

Samaja, Michele ;

Arena, Ross ;

Vicenzi, Marco ;

Guazzi, Maurizio D. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (22) :2136-2144

[8]

Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.[J].Rakesh C. Kukreja;Fadi Salloum;Anindita Das;Ramzi Ockaili;Chang Yin;Yvonne A. Bremer;Patrick W. Fisher;Michael Wittkamp;John Hawkins;Eric Chou;Amit K. Kukreja;Xiaoyin Wang;Vijay R. Marwaha;Lei Xi.Vascular Pharmacology.2005, 5

[9]

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K ATP channels in rabbits.[J].Fadi N. Salloum;Ramzi A. Ockaili;Michael Wittkamp;Vijay R. Marwaha;Rakesh C. Kukreja.Journal of Molecular and Cellular Cardiology.2005, 3

[10]

Effect of sildenafil on cardiac performance in patients with heart failure [J].

Hirata, K ;

Adji, A ;

Vlachopoulos, C ;

O'Rourke, MF .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (10) :1436-1440

← 1 2 →